Knowledge paper highlights biosimilars, biologics, AI-driven drug discovery and regulatory excellence as key growth drivers for the next phase of India's pharma expansion
Dengue, a mosquito-borne viral disease, is emerging as a growing public health threat across Africa
CEPI will commit up to US $50 million to fund preclinical research and Phase 1 clinical trials of Moderna’s mRNA-based vaccine candidate
While oncology contributed Rs. 16,100.9 million to remain company's largest therapy area, the key highlight was receipt of 11 new regulatory approvals for medicines and indications
We have the chance to build an IP estate that goes hand in hand with our generic pharmaceutical strength and build proprietary biological platforms
No approved vaccine or specific treatment currently available for Bundibugyo strain Ebola disease
The new CRS offering is delivered from WACKER’s Biotechnology Center in Munich
Pfizer says the broader dataset across all 25 serotypes strengthens confidence that the program can meet non-inferiority thresholds in its upcoming Phase 3 pediatric trials
Funding to accelerate development of integrated DNA platform supporting vaccines, gene therapies and advanced biologics
The private funding rose 38% amid growing international collaborations and CDMO demand
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
